Sofinnova Double Dealing
Clovis’ $200M EOS Buyout Gets Phase II Breast Cancer Prospect
By Randy Osborne and Cormac Sheridan
Wednesday, November 20, 2013
“It’s nice to make money with people you like,” said Antoine Papiernik, managing partner at Sofinnova Partners, about the $200 million-up-front deal engineered between Clovis Oncology Inc. and Ethical Oncology Science SpA (EOS).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.